Table 1.
Participant demographics.
| Participant demographics (N = 67) | |
|---|---|
| Age (IQR) | 47 (42–52) |
| Sex (% female) | 38.8 |
| BMI (IQR) | 30.3 (26.3–37.1) |
| Fasting insulin μU/mL (IQR) | 16.6 (10.6–26.4) |
| Fasting glucose mg/dL (SD) | 94.6 (12.0) |
| Log(HOMA-IR) (SD) | 0.63 (0.29) |
| Use of clozapine or olanzapine (% yes) | 28.4 |
| MTHFR 677 T carrier (%) | 28.8 |
| MTHFR 1298 C carrier (%) | 48.5 |
| Race (% non-caucasian) | 41.8 |
| Smoker (% yes) | 53.7 |
| CPZ equivalents, AAP only in mg (IQR) | 558.0 (367.0–727.2) |
| Total antipsychotic medication trials (IQR) | 5 (3–6) |
| Atypical antipsychotic medication trials (IQR) | 2 (2–4) |
| Typical antipsychotic medication trials (IQR) | 2 (1–3) |
| Time since diagnosis in years (IQR) | 19.0 (14.0–30.0) |
For continuous data, demographics were provided as means and standard deviations (SD) when values were normally distributed, otherwise as medians and interquartile ranges (IQR). CPZ, chlorpromazine; AAP, atypical antipsychotic.